The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global viral inactivation market size reached US$ 517.3 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,018.1 Million by 2027, exhibiting a growth rate (CAGR) of 11.7% during 2022-2027.
Biotherapeutic products contain viruses or they can become contaminated during the production process. Viruses are infectious particles that invade cells wherein they proliferate and result in various diseases. As a result, viral inactivation is widely used to inhibit coat proteins and degrade nucleic acid within the virus. At present, different methods of viral inactivation are available across the globe according to the characteristics of the virus and the type of biotherapeutic product. For instance, germicidal (UVC) light exposure helps inactivate viruses in hospitals and other critical public and military environments.
Human blood is a source of medicinal products that assists in the prevention and treatment of life-threatening diseases. Rising concerns about the transmission of blood-borne viruses through plasma-derived medicinal products represent one of the significant factors influencing the need for viral inactivation around the world. Several procedures for viral inactivation are nowadays used to assure the safety of blood plasma-derived protein solutions. Moreover, governing agencies of numerous countries are introducing stringent regulatory standards at an early stage in the development of biotherapeutic products. These standards are escalating the demand for viral inactivation to ensure the quality, safety, and efficacy of these products, thereby reducing the risk of cross-contamination. Apart from this, improved viral inactivation technologies and products are being employed in the food and beverage (F&B) industry to help control the transmission of enteric viruses and assure the safety of products. This, in confluence with the development of new physical methods like supercritical fluids, gas plasma, and pulsed electric fields, is anticipated to increase the reliability, convenience, and suitability of viral inactivation, thereby driving the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global viral inactivation market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, application and end use.
Breakup by Product:
Breakup by Application:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories, Merck KGaA, Parker Hannifin Corp, Rad Source Technologies, Sartorius AG, SGS SA, Terumo Corporation, Texcell, Vironova AB and WuXi AppTec.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Application, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Charles River Laboratories, Merck KGaA, Parker Hannifin Corp, Rad Source Technologies, Sartorius AG, SGS SA, Terumo Corporation, Texcell, Vironova AB and WuXi AppTec|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Pregnancy Detection Kits Market by Product (Home Pregnancy Tests (HPT), Digital Devices, and Others), Test Type (Urine Test for HCG, Blood Test for HCG, and Others), End User (Household, Gynecology Clinics, Hospitals), and Region 2023-2028
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at